Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab Administration Regimens in Melanoma
NCT02905266Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ). Started Oct 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02905266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905266.